A groundbreaking heart valve device, TriClip, has been introduced at the Medical University of South Carolina (MUSC), offering a safer and more effective treatment for patients suffering from tricuspid regurgitation. This minimally invasive procedure, approved by the FDA and CMS, marks a significant advancement in treating a condition that has been challenging to manage due to the high risks associated with traditional surgery.

Hemogenyx Pharmaceuticals has developed a clinical-grade assay to assess FLT3 protein expression in acute myeloid leukemia (AML) cells.

A cross-sectional study reveals patients with celiac disease who test positive for anti-tTG and anti-EMA antibodies show significantly higher rates of fibromyalgia (P = 0.04).

The HeLiX trial, a multicenter, placebo-controlled study, investigated tranexamic acid's impact on patients undergoing liver resection.

AIM ImmunoTech initiates development of Ampligen as a vaccine adjuvant for avian influenza, partnering with Amarex Clinical Research for IND application management.

Phase 3 study analysis reveals patients with psoriatic arthritis can safely transition from adalimumab to tofacitinib without a washout period, maintaining treatment efficacy.

University of Michigan researchers developed a groundbreaking sponge-like implant that helps track early disease progression in multiple sclerosis and guides treatment development.

A phase III clinical trial has demonstrated that the immunotherapy drug 'avelumab' significantly improves survival in patients with advanced bladder cancer, marking the first time an immune therapy has shown a survival advantage in this setting. The trial, led by Queen Mary University of London and Barts Cancer Centre, found a 31% reduction in the risk of death and extended median survival by over seven months.

Silo Pharma completed a pre-IND meeting with the FDA for SPC-15, an intranasal prophylactic treatment for PTSD and stress-induced anxiety disorders.

Researchers at the University of Melbourne have developed a proteomic blood test that can analyze thousands of proteins to diagnose rare genetic diseases in children within three days, requiring only 1ml of blood from infants.

The FDA expanded approval for delandistrogene moxeparvovec-rokl (ELEVIDYS) to include a broader range of Duchenne muscular dystrophy patients, including non-ambulatory individuals.

Russia's FMBA has initiated Phase I clinical trials for MCV-5, a novel vaccine against five serotypes (A, B, C, W, and Y) of meningococcus, a leading cause of meningitis.

Soligenix has initiated a Phase 2 clinical trial to evaluate SGX945 (dusquetide) for treating aphthous ulcers associated with Behçet's Disease, a chronic auto-immune condition.

A collaborative research team received a $3 million grant from the Department of Defense to investigate the neuropsychiatric symptoms of Parkinson's disease.

Invenio Imaging initiated a pivotal US study (ON-SITE) to evaluate its AI-based image analysis module for rapid lung cancer detection during bronchoscopy.

The Laboratory of Malaria Immunology and Vaccinology (LMIV) is leading efforts in developing malaria vaccines, focusing on reducing severe disease and eliminating malaria in low-transmission areas.

Ascletis Pharma has completed enrollment of 480 patients in a Phase III clinical trial for ASC40 (denifanstat), an oral tablet for moderate to severe acne.

A study involving 279 PCPs showed that using Chronic Disease Management Test (CDMT) significantly improved the detection of medication nonadherence and drug-drug interactions (DDIs).

Finnish researchers have developed an ML-powered tool called HASTEN that reduces virtual drug screening time from 6 months to under 10 days for 1.56 billion molecules.

The ESTEEM After Stroke program, a Phase III trial funded by the Medical Research Future Fund, is testing a community-based approach combining exercise, socialization, and cognitive activities to improve recovery and quality of life for stroke survivors. This innovative program, led by researchers from Hunter New England Local Health District, HMRI, and the University of Newcastle, aims to validate the effectiveness of environmental enrichment in stroke rehabilitation.